Science Translational Medicine · 2016 · 759 citations · 59 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis ResistanceApoptotic SignalingCancer Cell SignalingEnzyme InhibitionPharmacodynamics Of Anticancer AgentsTargeted Cancer TherapyApoptosis TargetingCancer Cell ApoptosisDna Damage-induced Cell DeathParp InhibitionParp Inhibitor ResistanceParp Inhibitor SensitivityPoly Adp-ribose Polymerase Inhibitors
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
59
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text
Medicine, Oncology, Pharmacology +17
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai, Shar-yin N. Huang, Benu Brata Das et al. · Cancer Research · 2012 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +17